Abstract:Pancreatic adenocarcinoma (PDA) is the 4th leading cause of cancer-related deaths in the US partly because of its resistance to conventional chemotherapies. Immunotherapies that improve survival in many cancers, almost universally fail in PDA. The resistance to immune checkpoint blockade is at least partially explained by the lack of T cells in the tumor microenvironment (TME) in PDA. As demonstrated previously, tumor cell-derived prostaglandin E2 (PGE2) is one of the tumor intrinsic factors that creates/supports immunosuppressive TME in PDA. The current study investigates how depleting tumor cell-derived PGE2 or disrupting its autocrine signaling through the cognate EP4 receptors on tumor cells reverses the T cell low, myeloid cell rich PDA TME and suppresses the tumor growth. Pharmacological blockade of EP4 receptors combined with anti-PD-1 and agonistic CD40 antibodies induced complete tumor regressions with a lasting vaccine effect. Knockout (KO) of Ptges, the gene encoding PGE2 synthesis enzyme mPGES-1, or EP4 receptor gene, Ptger4, in KrasG12D/P53R172H/Yfp/PdxCre (KPCY) pancreatic tumor cells was sufficient to abolish the growth of implanted tumors (p<0.0001 both). The rejection of the primary KO and rechallenge control tumors was T cell-dependent as it did not happen in hosts depleted of CD4+ and CD8+ T cells. Both KO tumor cells were more susceptible to TNF-a killing while their TMEs were enriched with central memory T cells and phagocytic macrophages and depleted of granulocytic myeloid-derived suppressor cells (gMDSC). Further analysis of Ptger4 tumors revealed changes in CCL2, CXCL9, and GM-CSF production probably causing the changes in TME. In addition, in both Ptges and Ptger4 KO tumors, the adenosine synthesis pathway was significantly downregulated probably due to decreased TGF-b signaling in tumor cells. When cultured ex vivo in hypoxic conditions, Ptger4 KO tumors made significantly less immunosuppressive adenosine (p<0.001). Consequently, 57% of Ptger4 KO tumors in adenosine deaminase inhibitor treated hosts accumulated enough adenosine to suppress the anti-tumor immune response and grow out. The study demonstrates a primary role for the tumor cell-intrinsic mPGES1-PGE2-EP4 signaling in creating immune-suppressive TME in PDA, suggesting EP4 blockade as a novel approach in the treatment of pancreatic cancer. Citation Format: Nune Markosyan, Il-Kyu Kim, Charu Arora, Liz Quinones, Noah Cheng, Ben Z. Stanger, Robert H. Vonderheide. Tumor cell-intrinsic mPGES-1-PGE2-EP4 signaling is a major immunosuppressive pathway in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Pancreatic Cancer; 2023 Sep 27-30; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(2 Suppl) nr B033.

Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner

The distinct role of CD73 in the progression of pancreatic cancer

A Tumor Intrinsic Role of CD73 in Pancreatic Adenocarcinoma

CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer.

Overexpression of CD73 in pancreatic ductal adenocarcinoma is associated with immunosuppressive tumor microenvironment and poor survival

Pancreatic cancer ductal cell of origin drives CD73-dependent generation of immunosuppressive adenosine

CD73, Tumor Plasticity and Immune Evasion in Solid Cancers

CD73 Is a Critical Immune Checkpoint in a Molecular Subtype of Pancreatic Cancer.

Pancreatic Cancer‐derived Exosomes Induce Apoptosis of T Lymphocytes Through the P38 MAPK‐mediated Endoplasmic Reticulum Stress

An IL6-Adenosine Positive Feedback Loop between CD73+ {gamma}{delta}Tregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers

Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion

An IL6–Adenosine Positive Feedback Loop Between CD73+ Γδtregs and CAFs Promotes Tumor Progression in Human Breast Cancer

Tumor cell senescence-induced macrophage CD73 expression is a critical metabolic immune checkpoint in the aging tumor microenvironment

The CD73 immune checkpoint promotes tumor cell metabolic fitness

CD73, a Promising Therapeutic Target of Diclofenac, Promotes Metastasis of Pancreatic Cancer through a Nucleotidase Independent Mechanism

Abstract LB-282: Dynamic Regulation of CD73 Expression in Cancer Associated Fibroblasts Enforces Immunosuppression Via a Feedforward Adenosinergic Pathway

CD73 Promotes Tumor Metastasis by Modulating RICS/RhoA Signaling and EMT in Gastric Cancer

Tumor Microenvironment Responsive CD8+ T Cells and Myeloid‐Derived Suppressor Cells to Trigger CD73 Inhibitor AB680‐Based Synergistic Therapy for Pancreatic Cancer

Abstract B033: Tumor cell-intrinsic mPGES-1-PGE2-EP4 signaling is a major immunosuppressive pathway in pancreatic cancer

CD73 on Cancer-Associated Fibroblasts Enhanced by the A2B-mediated Feedforward Circuit Enforces an Immune Checkpoint